Blog

The Hanover Insurance Group THG is expanding its motorcycle and off-road vehicle (ORV) insurance offerings across multiple U.S. states as part of its broader strategy to strengthen its total account

Roper Technologies, Inc. ROP continues to benefit from strength in its Application Software segment. Strong momentum across its Aderant, Deltek, Vertafore, PowerPlan and CentralReach businesses is

As AI adoption accelerates and Big Tech ramps up spending on AI infrastructure, demand for cybersecurity solutions is expected to rise alongside it. Greater AI integration increases the need for

USA Rare Earth, Inc. USAR has achieved a key milestone with the commissioning of Phase 1a of its commercial magnet production line at the Stillwater facility in Oklahoma. The development enables

Alibaba Group BABA closed its fiscal 2026 with a sobering message for investors — the cost of staying relevant in the artificial intelligence (AI) era is steep, and shareholders are footing the

CNO Financial Group, Inc. CNO is strategically positioned for growth, supported by strong collected premiums from life and health products, rising new annualized premiums and higher fee revenues. A

Analog Devices ADI shares have jumped 57.3% year to date, underperforming the Zacks Semiconductor - Analog and Mixed industry and the Zacks Computer and Technology sector’s appreciation of 67.4% and

Pediatrix Medical Group, Inc. MD is well-poised for growth, benefiting from stronger cash collections, a favorable payer mix and higher patient acuity in neonatology. Strategic acquisitions are

Applied Materials AMAT reported second-quarter fiscal 2026 non-GAAP earnings of $2.86 per share, which beat the Zacks Consensus Estimate by 6.5%. AMAT’s second-quarter fiscal 2026 non-GAAP earnings

Corcept Therapeutics’ CORT sole marketed drug, Korlym (mifepristone), which is approved for the treatment of Cushing’s syndrome, has been witnessing steady demand. Currently, the company’s top line

Argan, Inc.’s AGX fourth-quarter performance suggests that execution is becoming more than just an operating strength — it may be turning into a competitive moat. The company’s EBITDA rose to $56

ANI Pharmaceuticals’ ANIP business is moving deeper into specialty, with Rare Disease and Brands now positioned as the primary growth driver. The first quarter of 2026 reinforced that tilt, with

Getting big returns from financial portfolios, whether through stocks, bonds, ETFs, other securities, or a combination of all, is an investor's dream. But for income investors, generating consistent

All investors love getting big returns from their portfolio, whether it's through stocks, bonds, ETFs, or other types of securities. But for income investors, generating consistent cash flow from

Whether it's through stocks, bonds, ETFs, or other types of securities, all investors love seeing their portfolios score big returns. But for income investors, generating consistent cash flow from

Whether it's through stocks, bonds, ETFs, or other types of securities, all investors love seeing their portfolios score big returns. However, when you're an income investor, your primary focus is

Getting big returns from financial portfolios, whether through stocks, bonds, ETFs, other securities, or a combination of all, is an investor's dream. But for income investors, generating consistent

Whether it's through stocks, bonds, ETFs, or other types of securities, all investors love seeing their portfolios score big returns. But for income investors, generating consistent cash flow from

Getting big returns from financial portfolios, whether through stocks, bonds, ETFs, other securities, or a combination of all, is an investor's dream. But when you're an income investor, your

ANI Pharmaceuticals ANIP enters mid-2026 with momentum in its Rare Disease franchise, led by ACTH-based injection Cortrophin Gel. First-quarter 2026 results reinforced that mix shift, even as the

Investors interested in stocks from the Gaming sector have probably already heard of Churchill Downs (CHDN) and Red Rock Resorts (RRR). But which of these two stocks is more attractive to value

Investors interested in stocks from the Medical Info Systems sector have probably already heard of Doximity (DOCS) and Hims & Hers Health, Inc. (HIMS). But which of these two companies is the best

Investors interested in Medical Services stocks are likely familiar with Solventum (SOLV) and HealthEquity (HQY). But which of these two stocks offers value investors a better bang for their buck

Investors interested in stocks from the Internet - Services sector have probably already heard of HealthStream (HSTM) and Sify Technologies Limited (SIFY). But which of these two stocks is more

Investors interested in stocks from the Leisure and Recreation Services sector have probably already heard of Life Time Group Holdings, Inc. (LTH) and Vail Resorts (MTN). But which of these two